CytoDyn to Present at the H.C. Wainwright 27th Annual Global Investment Conference
CytoDyn (OTCQB: CYDY), a clinical-stage biotech company developing leronlimab, will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. The company's CFO, Robert E. Hoffman, will present on September 10 at 1:30 p.m. EDT at the Lotte New York Palace Hotel.
Leronlimab, the company's lead candidate, is a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with potential applications across multiple indications. The presentation will be available via webcast, and management will be available for one-on-one meetings with conference attendees.
CytoDyn (OTCQB: CYDY), società biotech in fase clinica che sviluppa leronlimab, parteciperà al H.C. Wainwright 27th Annual Global Investment Conference dall'8 al 10 settembre 2025. Il CFO, Robert E. Hoffman, terrà una presentazione il 10 settembre alle 13:30 EDT presso il Lotte New York Palace Hotel.
Leronlimab, il candidato di punta dell'azienda, è un anticorpo monoclonale umanizzato di prima classe mirato al recettore CCR5 e con potenziali applicazioni in diverse indicazioni. La presentazione sarà trasmessa via webcast e la dirigenza sarà disponibile per incontri individuali con i partecipanti alla conferenza.
CytoDyn (OTCQB: CYDY), una compañía biotecnológica en fase clínica que desarrolla leronlimab, participará en la H.C. Wainwright 27th Annual Global Investment Conference del 8 al 10 de septiembre de 2025. El director financiero, Robert E. Hoffman, ofrecerá una presentación el 10 de septiembre a la 1:30 p.m. EDT en el Lotte New York Palace Hotel.
Leronlimab, el candidato principal de la compañía, es un anticuerpo monoclonal humanizado de primera clase dirigido al receptor CCR5, con posibles aplicaciones en múltiples indicaciones. La presentación se podrá ver por webcast y la dirección estará disponible para reuniones individuales con los asistentes a la conferencia.
CytoDyn (OTCQB: CYDY)은 렐론리맙을 개발 중인 임상 단계의 바이오텍으로, 2025년 9월 8일부터 10일까지 열리는 H.C. Wainwright 27th Annual Global Investment Conference에 참가합니다. 최고재무책임자 Robert E. Hoffman는 9월 10일 오후 1시 30분(EDT)에 롯데 뉴욕 팰리스 호텔에서 발표할 예정입니다.
회사의 주요 후보물질인 렐론리맙은 CCR5 수용체를 표적하는 퍼스트인클래스 인간화 단일클론항체로, 여러 적응증에 적용될 가능성이 있습니다. 발표는 웹캐스트로 제공되며 경영진은 컨퍼런스 참석자들과의 일대일 미팅에도 응할 예정입니다.
CytoDyn (OTCQB: CYDY), une société biotechnologique en phase clinique développant le leronlimab, participera à la H.C. Wainwright 27th Annual Global Investment Conference du 8 au 10 septembre 2025. Le directeur financier, Robert E. Hoffman, présentera le 10 septembre à 13h30 EDT à l'hôtel Lotte New York Palace.
Le leronlimab, principal candidat de la société, est un anticorps monoclonal humanisé de première classe ciblant le récepteur CCR5, avec des applications potentielles dans plusieurs indications. La présentation sera diffusée en webcast et la direction sera disponible pour des rencontres individuelles avec les participants à la conférence.
CytoDyn (OTCQB: CYDY), ein Biotech-Unternehmen in der klinischen Phase, das Leromlimab entwickelt, nimmt an der H.C. Wainwright 27th Annual Global Investment Conference vom 8. bis 10. September 2025 teil. Der CFO, Robert E. Hoffman, wird am 10. September um 13:30 Uhr EDT im Lotte New York Palace Hotel präsentieren.
Leronlimab, der führende Kandidat des Unternehmens, ist ein First-in-Class humanisierter monoklonaler Antikörper, der den CCR5-Rezeptor adressiert und potenziell bei mehreren Indikationen anwendbar ist. Die Präsentation wird per Webcast verfügbar sein und das Management steht für persönliche Einzelgespräche mit Konferenzteilnehmern zur Verfügung.
- None.
- None.
VANCOUVER, Washington, Aug. 28, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage biotechnology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, today announced that management will participate in the H.C. Wainwright 27th Annual Global Investment Conference being held September 8 to 10, 2025, at the Lotte New York Palace Hotel in New York City.
Robert E. Hoffman, Chief Financial Officer, will deliver a presentation on Wednesday, September 10, at 1:30 p.m. EDT, which will be accessible via webcast here, and will be available for one-on-one meetings with registered conference attendees.
About CytoDyn
CytoDyn is a clinical-stage biotechnology company dedicated to advancing leronlimab, a first-in-class humanized monoclonal antibody that targets the CCR5 receptor, a key regulator of immune function implicated in cancer, infectious diseases, and autoimmune disorders.
Guided by a mission to improve patients’ quality of life through therapeutic innovation, CytoDyn is committed to integrity, responsibility, and service as it works to bring transformative treatments to patients worldwide.
For more information, please visit www.cytodyn.com and follow us on LinkedIn.
Investor Relations
CytoDyn Inc.
ir@cytodyn.com
Media Contacts
Rob Haney, Ph.D., or Ignacio Guerrero-Ros, Ph.D.
Russo Partners, LLC
CytoDyn@russopartnersllc.com
FAQ
When is CytoDyn presenting at the H.C. Wainwright Conference 2025?
What is CytoDyn's main drug candidate leronlimab?
Who will represent CYDY at the H.C. Wainwright Conference?
How can investors access CytoDyn's H.C. Wainwright conference presentation?
